{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:34:09Z","timestamp":1787070849978,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The role of ascorbic acid in cancer therapy is mainly due to its structural similarity with glucose. When supplemented intravenously in high dose, ascorbic acid can get into the cancer cells and induce apoptosis by causing mitochondrial damage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>The aim was to study the efficacy of high-dose intravenous (IV) ascorbic acid as monotherapy in cancer patients following ketogenic diet and its role in improving the quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      C-reactive protein (CRP) and erythrocyte sedimentation rates (ESRs) were considered as parameters to determine the efficacy of the treatment, and substantial decrease in both the levels was observed within 1-week treatment. CRP levels declined from 3.1946 \u00b1 3.2508 mg\/L to 1.0606 \u00b1 0.6706 mg\/L (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 2.27E-10), whereas ESR levels declined from 64.1333 \u00b1 38.8253 mm\/h to 31.6 \u00b1 16.5520 mm\/h (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0041). A decline in these parameters shows the association of ascorbic acid in reducing the inflammatory response in cancer. The renal effect of ascorbic acid was also studied by analyzing the creatinine level pre- and postascorbic acid treatment sessions, and it raised from 0.8526 \u00b1 0.22904 to 1.1666 \u00b1 0.2894 mg\/dL (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 1.18E-14). This showed the renal impact of ascorbic acid.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The study highlighted the clinical benefit of IV ascorbic acid in the reduction of inflammatory response in cancer patients. The renal adverse events associated with ascorbic acid alarm the use with caution and therapeutic drug monitoring for ascorbic acid.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_973_19","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:06:26Z","timestamp":1639526786000},"page":"1583-1586","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Effect of high-dose intravenous ascorbic acid on cancer patients following ketogenic diet"],"prefix":"10.4103","volume":"17","author":[{"given":"Stelvin","family":"Sebastian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aby","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Joby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjo","family":"Saijan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jobin Kunjumon","family":"Vilapurathu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-50-20241021","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3747\/co.25.3790","article-title":"Intravenous Vitamin C in the supportive care of cancer patient","volume":"2","author":"Klimant","year":"2018","journal-title":"Curr Oncol"},{"key":"R2-50-20241021","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/1479-5876-10-189","article-title":"Effect of high-dose intravenous Vitamin C on inflammation in cancer patients","volume":"10","author":"Mikirova","year":"2012","journal-title":"J Transl Med"},{"key":"R3-50-20241021","first-page":"188","article-title":"Potential mechanism of action for Vitamin C in cancer","volume":"8","author":"Vissers","year":"2018","journal-title":"Front Physiol"},{"key":"R4-50-20241021","first-page":"333","article-title":"Ascorbic acid in cancer","volume":"6","author":"Rangarajan","year":"2014","journal-title":"J Cancer Sci Ther"},{"key":"R5-50-20241021","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3346\/jkms.2007.22.1.7","article-title":"Changes of terminal cancer patient health-related quality of life after high dose Vitamin C administration","volume":"22","author":"Yeom","year":"2006","journal-title":"J Korean Med Sci"},{"key":"R7-50-20241021","doi-asserted-by":"crossref","first-page":"48","DOI":"10.22259\/2638-5074.0101007","article-title":"The ketogenic diet and cancer","volume":"1","author":"Aponte","year":"2018","journal-title":"Arch Oncol Cancer Ther"},{"key":"R8-50-20241021","first-page":"983","article-title":"Intravenous Vitamin C administration improves quality of life in Breast cancer patients during chemo\/Radiotherapy and aftercare","volume":"25","author":"Vollbracht","year":"2011","journal-title":"In Vivo"},{"key":"R9-50-20241021","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1445-5994.1994.tb01477.x","article-title":"Acute oxalate nephropathy after a massive intravenous dose of ascorbic acid","volume":"24","author":"Wong","year":"1994","journal-title":"Aust ZN J Med"},{"key":"R10-50-20241021","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.freeradbiomed.2009.02.016","article-title":"Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects","volume":"47","author":"Verrax","year":"2009","journal-title":"Free Radic Biol Med"},{"key":"R11-50-20241021","first-page":"31","article-title":"Effectiveness of Vitamin C in the treatment of anemia in patients with chronic disease","volume":"4","author":"Rodrigez","year":"2016","journal-title":"RRJPPS"},{"key":"R12-50-20241021","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2307\/4012087","article-title":"Antioxidants may help cancer thrive","volume":"157","author":"Raloff","year":"2009","journal-title":"Sci News"},{"key":"R13-50-20241021","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1479-5876-6-50","article-title":"Anti-angiogenic effect of the high dose of ascorbic acid","volume":"6","author":"Mikirova","year":"2008","journal-title":"Transl Med"},{"key":"R14-50-20241021","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/0003-4819-140-7-200404060-00010","article-title":"Vitamin C pharmacokinetics: Implications for oral and intravenous use","volume":"140","author":"Padayatty","year":"2004","journal-title":"Ann Intern Med"},{"key":"R15-50-20241021","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/B:AGEN.0000029390.09354.f8","article-title":"Novel function of ascorbic acid as an angiostatic factor","volume":"6","author":"Ashino","year":"2003","journal-title":"Angiogenesis"},{"key":"R16-50-20241021","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/jnci\/83.8.547","article-title":"Ascorbic acid: Biological functions and relation to cancer","volume":"83","author":"Henson","year":"1994","journal-title":"J Natl Cancer Inst"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_973_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:37:38Z","timestamp":1787067458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_973_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_973_19","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}